Mirdametinib

GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

Side effects, and when to stop

The following serious adverse reactions are described elsewhere in the labeling:

Ocular Toxicity
Left Ventricular Dysfunction
Dermatologic Adverse Reactions
Embryo-Fetal Toxicity

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Mirdametinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/mirdametinib
APA 7th: sofidex. (2026, August 3). Mirdametinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/mirdametinib
AMA 11th: Mirdametinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/mirdametinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.